Pacific Shuanglin Bio pharmacy Co Ltd (000403)

Currency in CNY
18.35
+0.24(+1.33%)
Closed·

000403 Financial Summary

Key Ratios

P/E Ratio24.34
Price/Book2.15
Debt / Equity8.18%
Return on Equity9.16%
Dividend Yield3.37%
EBITDA913.93M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2019
01/01
2020
01/01
2021
01/01
2022
01/01
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.74%
Dividend Yield
3.37%
Industry Median 1.51%
Annualised payout
0.62
Paid unevenly
5-Years Growth
+49.27%
Growth Streak

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.84
(+13.56% Upside)

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.09 / 0.28
Revenue / Forecast
374.65M / --
EPS Revisions
Last 90 days

FAQ

What were Pacific Shuanglin Bio pharmacy's earnings for the latest quarter?

The Pacific Shuanglin Bio pharmacy EPS (TTM) is 0.74. Pacific Shuanglin Bio pharmacy reported sales of 374.65, net income of 89.09, and EPS of 0.09 for the latest quarter.

What was Pacific Shuanglin Bio pharmacy's net income for the latest quarter?

Pacific Shuanglin Bio pharmacy's net income for the latest quarter was 89.09.

How did Pacific Shuanglin Bio pharmacy's performance compare year-over-year in the latest quarter?

The company's revenue moved from 764.42 in the previous quarter to 374.65 in the latest quarter, and net income moved from 202.59 to 89.09 compared to the previous quarter.

What is Pacific Shuanglin Bio pharmacy's net profit margin on a TTM basis?

Pacific Shuanglin Bio pharmacy's trailing twelve months (TTM) net profit margin is 28.08%.

How does Pacific Shuanglin Bio pharmacy's debt to equity ratio compare to industry standards?

Pacific Shuanglin Bio pharmacy's total debt-to-equity ratio is 8.18%.

What is Pacific Shuanglin Bio pharmacy's return on investment on a TTM basis?

Pacific Shuanglin Bio pharmacy's trailing twelve months (TTM) return on investment (ROI) is 9.16%.

Did Pacific Shuanglin Bio pharmacy gain or lose cash last quarter?

In the latest quarter, Pacific Shuanglin Bio pharmacy's net change in cash was -654.44 million.

What were Pacific Shuanglin Bio pharmacy's total assets and liabilities in the latest quarter?

As of the latest quarter, Pacific Shuanglin Bio pharmacy reported total assets of 9,196.70 million and total liabilities of 827.87 million.

How has Pacific Shuanglin Bio pharmacy's total revenue grown this year?

Pacific Shuanglin Bio pharmacy's total revenue was 764.42 in the previous quarter and 374.65 in the latest quarter.

What is Pacific Shuanglin Bio pharmacy's gross margin on a TTM basis?

Pacific Shuanglin Bio pharmacy's trailing twelve months (TTM) gross margin is 48.54%.

What was Pacific Shuanglin Bio pharmacy's revenue per share for the latest quarter?

Pacific Shuanglin Bio pharmacy's revenue per share for the latest quarter was 6.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.